Menu

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga Insights 1 hour ago

Movers

Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market cap stands

Gainers

  • Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session.
  • enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market cap stands at $120.6 million.
  • Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock moved upwards by 28.57% to $0.18.
  • QTREX Quantum (NASDAQ:QTEX) shares increased by 18.57% to $1.17. The company's market cap stands at $65.9 million.
  • Traws Pharma (NASDAQ:TRAW) stock increased by 17.95% to $0.29. The market value of their outstanding shares is at $3.8 million.
  • Cumberland Pharma (NASDAQ:CPIX) stock rose 17.48% to $7.19. The market value of their outstanding shares is at $91.6 million. As per the news, the Q3 earnings report came out 2 days ago.

Losers

  • Estrella Immunopharma (NASDAQ:ESLA) stock decreased by 45.0% to $0.44 during Thursday's regular session. The company's market cap stands at $34.5 million.
  • SeaStar Medical Holding (NASDAQ:ICU) shares decreased by 41.67% to $1.12. The market value of their outstanding shares is at $10.2 million. As per the press release, Q3 earnings came out yesterday.
  • Jin Medical International (NASDAQ:ZJYL) shares fell 31.38% to $3.37. The company's market cap stands at $38.4 million.
  • electroCore (NASDAQ:ECOR) stock declined by 28.28% to $5.53. The market value of their outstanding shares is at $69.5 million.
  • Tessera Defense (AMEX:HLSQ) shares fell 27.95% to $0.03.
  • OptimizeRx (NASDAQ:OPRX) stock declined by 18.83% to $7.26. The market value of their outstanding shares is at $165.5 million. As per the news, the Q3 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Read the original